

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 1 of 33

I. POLICY DESCRIPTION:

Vascular Endothelial Growth Factor (VEGF) Inhibitors - Beovu (brolucizumab), Byooviz (ranibizumab-nuna), Cimerli (ranibizumab-eqrn), Eylea (aflibercept), Eylea HD (aflibercept), Lucentis (ranibizumab), Macugen (pegaptanib), Pavblu (aflibercept-ayyh), Susvimo (ranibizumab) and Vabysmo (faricimab-svoa)

II. RESPONSIBLE PARTIES:

Medical Management Administration, Pharmacy Department, Utilization Management, Integrated Care Management, Claims Department

III. DEFINITIONS:

Beovu is a recombinant humanized monoclonal antibody vascular endothelial growth factor (VEGF) inhibitor that binds to the 3 major isoforms of VEGF-A, thereby suppressing endothelial cell proliferation, neovascularization, and vascular permeability to slow vision loss.

Byooviz, Cimerli, Lucentis, and Susvimo are a recombinant humanized monoclonal antibody fragments which bind to and inhibit human vascular endothelial growth factor A (VEGF-A). They inhibit VEGF-A from binding to its receptors and thereby suppressing neovascularization and slowing vision loss.

Eylea, Eylea HD and Pavblu are recombinant fusion proteins that acts as a decoy receptor for vascular endothelial growth factor-A (VEGF-A) and placental growth factor (P_LGF). Eylea binds to VEGF-A and P_LGF and inhibits binding and activating of endothelial cell receptors, thereby suppressing neovascularization and slowing vision loss.

Macugen is an aptamer, a pegylated modified oligonucleotide that binds to VEGF₁₆₅ and inhibits it. VEGF₁₆₅ causes abnormal blood vessel growth and leakage associated in wet Age-Related Macular Degeneration (AMD).

Vabysmo is a recombinant humanized bispecific antibody that inhibits vascular endothelial growth factor A (VEGF-A), resulting in suppression of endothelial cell proliferation, neovascularization and vascular permeability. It also inhibits angiopoietin-2 (Ang-2), which promotes vascular stability and desensitizes blood vessels to effects of VEGF-A.

IV. POLICY:

VEGF Inhibitors will be considered medically necessary once the following coverage criteria is met. Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. VEGF inhibitors

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 2 of 33

for other compendial supported indications will follow the criteria of trial and failure of Avastin followed by Lucentis or Byooviz for 3 months.

Chart notes must be submitted to confirm diagnosis and previous treatment(s).

INITIAL REQUEST:

1. Neovascular (Wet) Age-Related Macular Degeneration (AMD) (Beovu, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis, Macugen, Pavblu, Susvimo, Vabsymo)

A. Member is ≥ 50 years of age;

AND

B. Prescribed by or in consultation with an ophthalmologist;

AND

C. Member has ALL of the following:

a. Early Treatment Diabetic Retinopathy Study (ETDRS) chart with a best corrected visual acuity of 20/40 to 20/320;

AND

b. Primary or recurrent sub foveal choroidal neovascularization (CNV) lesions (any subtype) secondary to AMD, including juxta foveal lesions that affect the fovea as evidenced by Fluorescein Angiography (FA);

AND

D. ONE of the following:

a. If request is for Byooviz or Lucentis then member has trial and failure of Avastin for 3 doses or has a contraindication to Avastin;

OR

b. If request is for all other VEGFs then member has a trial and failure of Avastin for 3 doses or has a contraindication to Avastin followed by a trial and failure of Lucentis or Byooviz for 3 doses or has a contraindication to Lucentis or Byooviz;

AND

E. Authorization is for no more than 12 months

2. Macular Edema Following Retinal Vein Occlusion (RVO) (Byooviz, Cimerli, Eylea, Lucentis, Pavblu, Vabysmo)

A. Member is ≥ 18 years of age;

AND

B. Prescribed by or in consultation with an ophthalmologist;

AND

C. Member has ALL of the following;

a. Early Treatment Diabetic Retinopathy Study (ETDRS) chart with a best corrected visual acuity of 20/25 to 20/320;

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 3 of 33

AND

b. History of Macular edema \leq 12 months;

AND

D. ONE of the following:

a. If request is for Byooviz or Lucentis then member has trial and failure of Avastin for 3 doses or has a contraindication to Avastin;

OR

b. If request is for all other VEGFs then member has a trial and failure of Avastin for 3 doses or has a contraindication to Avastin followed by a trial and failure of Lucentis or Byooviz for 3 doses or has a contraindication to Lucentis or Byooviz;

AND

E. Authorization is for no more than 12 months

3. Diabetic Macular Edema (DME) (Beovu, Cimerli, Eylea, Eylea HD, Lucentis, Pavblu, Vabsymo)

A. Member is \geq 18 years of age;

AND

B. Prescribed by or in consultation with an ophthalmologist;

AND

C. Member has ALL of the following;

a. Early Treatment Diabetic Retinopathy Study (ETDRS) chart with a best corrected visual acuity of 20/200 or better;

AND

b. Type 1 or type 2 diabetes;

AND

c. Central macular sub-field thickness according to Spectral Domain Optical Coherence Tomography (SD-OCT) of at least 300 microns (Heidelberg Spectralis OCT or equivalent);

AND

d. Intraocular pressure (IOP) of 21 mmHg or less

AND

D. ONE of the following:

a. If request is for Lucentis then member has trial and failure of Avastin for 3 doses or has a contraindication to Avastin;

OR

b. If request is for all other VEGFs then member has a trial and failure of Avastin for 3 doses or has a contraindication to Avastin followed by a trial and failure of Lucentis for 3 doses or has a contraindication to Lucentis;

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 4 of 33

AND

E. Authorization is for no more than 12 months

4. Diabetic Retinopathy (DR) in Patients with Diabetic Macular Edema (DME) (Cimerli, Eylea, Eylea HD, Lucentis, Pavblu)

A. Member is ≥ 18 years of age;

AND

B. Prescribed by or in consultation with an ophthalmologist;

AND

C. Member has ALL of the following;

a. Early Treatment Diabetic Retinopathy Study (ETDRS) chart with a best corrected visual acuity of 20/320 or better;

AND

b. Type 1 or type 2 diabetes;

AND

c. neovascularization secondary to diabetic retinopathy

AND

D. ONE of the following:

a. If request is for Lucentis then member has trial and failure of Avastin for 3 doses or has a contraindication to Avastin;

OR

b. If request is for all other VEGFs then member has a trial and failure of Avastin for 3 doses or has a contraindication to Avastin followed by a trial and failure of Lucentis for 3 doses or has a contraindication to Lucentis;

AND

E. Authorization is for no more than 12 months

5. Myopic Choroidal Neovascularization (Cimerli, Byooviz, Lucentis)

A. Member is ≥ 18 years of age;

AND

B. Prescribed by or in consultation with an ophthalmologist;

AND

C. Member has ALL of the following;

a. Visual impairment due to choroidal neovascularization (CNV) secondary to PM;

AND

b. Best corrected visual acuity (BCVA) in the study eye > 24 and < 78 Early Treatment Diabetic Retinopathy Study (ETDRS) letters;

AND

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 5 of 33

c. High myopia (> -6D), anterior-posterior elongation > 26 mm; posterior changes compatible with the pathologic myopia;

AND

d. Either lesion types in the study eye: subfoveal, juxtafoveal, extrafoveal;

AND

D. ONE of the following:

a. If request is for Byooviz or Lucentis then member has trial and failure of Avastin for 3 doses or has a contraindication to Avastin;

OR

b. If request is for all other VEGFs then member has a trial and failure of Avastin for 3 doses or has a contraindication to Avastin followed by a trial and failure of Lucentis or Byooviz for 3 doses or has a contraindication to Lucentis or Byooviz;

AND

E. Authorization is for no more than 12 months

6. Retinopathy of prematurity (ROP) (Eylea)

A. ONE of the following:

a. Member was premature with a a birth weight of ≤ 1500 g or a gestational age of 30 weeks or less (as defined by the attending neonatologist);

OR

b. Member had a birth weight between 1500 and 2000g or a gestational age of > 30 weeks who was believed by their attending pediatrician or neonatologist to be at risk for ROP (i.e., infants with hypotension requiring inotropic support, infants who received oxygen supplementation for more than a few days, or infants who received oxygen without saturation monitoring);

AND

B. Prescribed by or in consultation with an ophthalmologist;

AND

C. Member has a confirmed diagnosis of ROP as **ONE** of the following:

a. Zone I ROP: any stage with plus disease;

OR

b. Zone I ROP: stage 3, no plus disease;

OR

c. Zone II: stage 2 or 3 with plus disease;

AND

D. Member must have tried and failed Avastin for 3 doses or has a contraindication to Avastin;

AND

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 6 of 33

E. Authorization is for no more than 12 months

RENEWAL REQUEST:

1. All Indications

A. Member has a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss);

AND

B. Member did not experience any adverse effects while on therapy;

AND

C. Authorization is for no more than 12 months

V. LIMITATIONS/ EXCLUSIONS:

VEGF Inhibitors are considered to be experimental and investigational if prescribed for indications that have not been approved by the FDA nor supported by compendial literature; and will not be covered under this policy.

VI. APPLICABLE PROCEDURE CODES:

CPT	Description
J0177	Injection, aflibercept hd, 1 mg (Eylea HD)
J0178	Injection, aflibercept, 1 mg (Eylea)
J0179	Injection, brolocizumab-dbl, 1 mg (Beovu)
J2503	Injection, pegaptanib sodium, 0.3mg (Macugen)
J2777	Injection, faricimab-svoa, 0.1 mg (Vabysmo)
J2778	Injection, ranibizumab, 0.1 mg (Lucentis)
J2779	Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg

VII. APPLICABLE DIAGNOSIS CODES:

CODE	Description
E08.311	Diab due to undrl cond w unsp diabetic rtnop w macular edema
E08.3211	Diabetes with mild nonp rtnop with macular edema, right eye
E08.3212	Diabetes with mild nonp rtnop with macular edema, left eye
E08.3213	Diabetes with mild nonp rtnop with macular edema, bilateral
E08.3219	Diabetes with mild nonp rtnop with macular edema, unsp

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 7 of 33

E08.3311	Diabetes with moderate nonp rtnop with macular edema, r eye
E08.3312	Diab with moderate nonp rtnop with macular edema, left eye
E08.3313	Diabetes with moderate nonp rtnop with macular edema, bi
E08.3319	Diabetes with moderate nonp rtnop with macular edema, unsp
E08.3411	Diabetes with severe nonp rtnop with macular edema, r eye
E08.3412	Diabetes with severe nonp rtnop with macular edema, left eye
E08.3413	Diabetes with severe nonp rtnop with macular edema, bi
E08.3419	Diabetes with severe nonp rtnop with macular edema, unsp
E08.3511	Diab with prolif diabetic rtnop with macular edema, r eye
E08.3512	Diab with prolif diabetic rtnop with macular edema, left eye
E08.3513	Diabetes with prolif diabetic rtnop with macular edema, bi
E08.3519	Diabetes with prolif diabetic rtnop with macular edema, unsp
E08.37X1	Diab with diabetic macular edema, resolved fol trtmt, r eye
E08.37X2	Diab with diab macular edema, resolved fol trtmt, left eye
E08.37X3	Diabetes with diabetic macular edema, resolved fol trtmt, bi
E08.37X9	Diab with diabetic macular edema, resolved fol trtmt, unsp
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabeticretinopathy with macular edema
E09.3211	Drug/chem diab with mild nonp rtnop with mclr edema, r eye
E09.3212	Drug/chem diab with mild nonp rtnop with mclr edema, l eye
E09.3213	Drug/chem diab with mild nonp rtnop with macular edema, bi
E09.3219	Drug/chem diab with mild nonp rtnop with macular edema, unsp
E09.3311	Drug/chem diab with mod nonp rtnop with macular edema, r eye
E09.3312	Drug/chem diab with mod nonp rtnop with macular edema, l eye
E09.3313	Drug/chem diab with mod nonp rtnop with macular edema, bi
E09.3319	Drug/chem diab with mod nonp rtnop with macular edema, unsp
E09.3411	Drug/chem diab with severe nonp rtnop with mclr edema, r eye
E09.3412	Drug/chem diab with severe nonp rtnop with mclr edema, l eye
E09.3413	Drug/chem diab with severe nonp rtnop with macular edema, bi
E09.3419	Drug/chem diab with severe nonp rtnop with mclr edema, unsp
E09.3511	Drug/chem diab with prolif diab rtnop with mclr edema, r eye
E09.3512	Drug/chem diab with prolif diab rtnop with mclr edema, l eye
E09.3513	Drug/chem diab with prolif diab rtnop with macular edema, bi
E09.3519	Drug/chem diab with prolif diab rtnop with mclr edema, unsp
E09.37X1	Drug/chem diab w diab mclr edma, resolved fol trtmt, r eye
E09.37X2	Drug/chem diab w diab mclr edma, resolved fol trtmt, l eye
E09.37X3	Drug/chem diab with diab mclr edema, resolved fol trtmt, bi
E09.37X9	Drug/chem diab with diab mclr edma, resolved fol trtmt, unsp

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 8 of 33

E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.3211	Type 1 diab with mild nonp rtnop with macular edema, r eye
E10.3212	Type 1 diab with mild nonp rtnop with macular edema, l eye
E10.3213	Type 1 diabetes with mild nonp rtnop with macular edema, bi
E10.3219	Type 1 diab with mild nonp rtnop with macular edema, unsp
E10.3311	Type 1 diab with mod nonp rtnop with macular edema, r eye
E10.3312	Type 1 diab with mod nonp rtnop with macular edema, l eye
E10.3313	Type 1 diab with moderate nonp rtnop with macular edema, bi
E10.3319	Type 1 diab with mod nonp rtnop with macular edema, unsp
E10.3411	Type 1 diab with severe nonp rtnop with macular edema, r eye
E10.3412	Type 1 diab with severe nonp rtnop with macular edema, l eye
E10.3413	Type 1 diab with severe nonp rtnop with macular edema, bi
E10.3419	Type 1 diab with severe nonp rtnop with macular edema, unsp
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.3211	Type 2 diab with mild nonp rtnop with macular edema, r eye
E11.3212	Type 2 diab with mild nonp rtnop with macular edema, l eye
E11.3213	Type 2 diabetes with mild nonp rtnop with macular edema, bi
E11.3219	Type 2 diab with mild nonp rtnop with macular edema, unsp
E11.3311	Type 2 diab with mod nonp rtnop with macular edema, r eye
E11.3312	Type 2 diab with mod nonp rtnop with macular edema, l eye
E11.3313	Type 2 diab with moderate nonp rtnop with macular edema, bi

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 9 of 33

E11.3319	Type 2 diab with mod nonp rtnop with macular edema, unsp
E11.3411	Type 2 diab with severe nonp rtnop with macular edema, r eye
E11.3412	Type 2 diab with severe nonp rtnop with macular edema, l eye
E11.3413	Type 2 diab with severe nonp rtnop with macular edema, bi
E1.3419	Type 2 diab with severe nonp rtnop with macular edema, unsp
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macularedema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.3211	Oth diabetes with mild nonp rtnop with macular edema, r eye
E13.3212	Oth diab with mild nonp rtnop with macular edema, left eye
E13.3213	Oth diabetes with mild nonp rtnop with macular edema, bi
E13.3219	Oth diabetes with mild nonp rtnop with macular edema, unsp
E13.3311	Oth diab with moderate nonp rtnop with macular edema, r eye
E13.3312	Oth diab with moderate nonp rtnop with macular edema, l eye
E13.3313	Oth diabetes with moderate nonp rtnop with macular edema, bi
E13.3319	Oth diab with moderate nonp rtnop with macular edema, unsp
E13.3411	Oth diab with severe nonp rtnop with macular edema, r eye
E13.3412	Oth diab with severe nonp rtnop with macular edema, left eye
E13.3413	Oth diabetes with severe nonp rtnop with macular edema, bi
E13.3419	Oth diabetes with severe nonp rtnop with macular edema, unsp
E13.3511	Oth diab with prolif diab rtnop with macular edema, r eye
E13.3512	Oth diab with prolif diab rtnop with macular edema, left eye
E13.3513	Oth diab with prolif diabetic rtnop with macular edema, bi
E13.3519	Oth diab with prolif diabetic rtnop with macular edema, unsp

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 10 of 33

E13.37X1	Oth diab with diab macular edema, resolved fol trtmt, r eye
E13.37X2	Oth diab with diab macular edema, resolved fol trtmt, l eye
E13.37X3	Oth diab with diabetic macular edema, resolved fol trtmt, bi
E13.37X9	Oth diab with diab macular edema, resolved fol trtmt, unsp
H35.059	Retinal neovascularization, unspecified, unspecified eye
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 11 of 33

E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 12 of 33

E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 13 of 33

E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 14 of 33

E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 15 of 33

E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 16 of 33

E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 17 of 33

E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 18 of 33

E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 19 of 33

E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 20 of 33

E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye
H34.811	Central retinal vein occlusion, right eye
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.812	Central retinal vein occlusion, left eye
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.813	Central retinal vein occlusion, bilateral
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable
H34.819	Central retinal vein occlusion, unspecified eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 21 of 33

H34.8190	Central retinal vein occlusion, unspecified eye, with macular edema
H34.8191	Central retinal vein occlusion, unspecified eye, with retinal neovascularization
H34.8192	Central retinal vein occlusion, unspecified eye, stable
H34.821	Venous engorgement, right eye
H34.822	Venous engorgement, left eye
H34.823	Venous engorgement, bilateral
H34.829	Venous engorgement, unspecified eye
H34.831	Tributary (branch) retinal vein occlusion, right eye
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.832	Tributary (branch) retinal vein occlusion, left eye
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable
H34.833	Tributary (branch) retinal vein occlusion, bilateral
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H34.839	Tributary (branch) retinal vein occlusion, unspecified eye
H34.8390	Tributary (branch) retinal vein occlusion, unspecified eye, with macular edema
H34.8391	Tributary (branch) retinal vein occlusion, unspecified eye, with retinal neovascularization
H34.8392	Tributary (branch) retinal vein occlusion, unspecified eye, stable
H34.9	Unspecified retinal vascular occlusion
H35.051	Retinal neovascularization, unspecified, right eye
H35.052	Retinal neovascularization, unspecified, left eye
H35.053	Retinal neovascularization, unspecified, bilateral
H35.059	Retinal neovascularization, unspecified, unspecified eye
H35.101	Retinopathy of prematurity, unspecified, right eye
H35.102	Retinopathy of prematurity, unspecified, left eye
H35.103	Retinopathy of prematurity, unspecified, bilateral
H35.109	Retinopathy of prematurity, unspecified, unspecified eye
H35.111	Retinopathy of prematurity, stage 0, right eye
H35.112	Retinopathy of prematurity, stage 0, left eye
H35.113	Retinopathy of prematurity, stage 0, bilateral
H35.119	Retinopathy of prematurity, stage 0, unspecified eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 22 of 33

H35.121	Retinopathy of prematurity, stage 1, right eye
H35.122	Retinopathy of prematurity, stage 1, left eye
H35.123	Retinopathy of prematurity, stage 1, bilateral
H35.129	Retinopathy of prematurity, stage 1, unspecified eye
H35.131	Retinopathy of prematurity, stage 2, right eye
H35.132	Retinopathy of prematurity, stage 2, left eye
H35.133	Retinopathy of prematurity, stage 2, bilateral
H35.139	Retinopathy of prematurity, stage 2, unspecified eye
H35.141	Retinopathy of prematurity, stage 3, right eye
H35.142	Retinopathy of prematurity, stage 3, left eye
H35.143	Retinopathy of prematurity, stage 3, bilateral
H35.149	Retinopathy of prematurity, stage 3, unspecified eye
H35.151	Retinopathy of prematurity, stage 4, right eye
H35.152	Retinopathy of prematurity, stage 4, left eye
H35.153	Retinopathy of prematurity, stage 4, bilateral
H35.159	Retinopathy of prematurity, stage 4, unspecified eye
H35.161	Retinopathy of prematurity, stage 5, right eye
H35.162	Retinopathy of prematurity, stage 5, left eye
H35.163	Retinopathy of prematurity, stage 5, bilateral
H35.169	Retinopathy of prematurity, stage 5, unspecified eye
H35.30	Unspecified macular degeneration (age-related)
H35.31	Nonexudative age-related macular degeneration
H35.3110	Nonexudative age-related macular degeneration, right eye, stage unspecified
H35.3111	Nonexudative age-related macular degeneration, right eye, early dry stage
H35.3112	Nonexudative age-related macular degeneration, right eye, intermediate dry stage
H35.3113	Nonexudative age-related macular degeneration, right eye, advanced atrophic without subfoveal involvement
H35.3114	Nonexudative age-related macular degeneration, right eye, advanced atrophic with subfoveal involvement
H35.3120	Nonexudative age-related macular degeneration, left eye, stage unspecified
H35.3121	Nonexudative age-related macular degeneration, left eye, early dry stage
H35.3122	Nonexudative age-related macular degeneration, left eye, intermediate dry stage
H35.3123	Nonexudative age-related macular degeneration, left eye, advanced atrophic without subfoveal involvement
H35.3124	Nonexudative age-related macular degeneration, left eye, advanced atrophic with subfoveal involvement
H35.3130	Nonexudative age-related macular degeneration, bilateral, stage unspecified
H35.3131	Nonexudative age-related macular degeneration, bilateral, early dry stage
H35.3132	Nonexudative age-related macular degeneration, bilateral, intermediate dry stage

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 23 of 33

H35.3133	Nonexudative age-related macular degeneration, bilateral, advanced atrophic without subfoveal involvement
H35.3134	Nonexudative age-related macular degeneration, bilateral, advanced atrophic with subfoveal involvement
H35.3190	Nonexudative age-related macular degeneration, unspecified eye, stage unspecified
H35.3191	Nonexudative age-related macular degeneration, unspecified eye, early dry stage
H35.3192	Nonexudative age-related macular degeneration, unspecified eye, intermediate dry stage
H35.3193	Nonexudative age-related macular degeneration, unspecified eye, advanced atrophic without subfoveal involvement
H35.3194	Nonexudative age-related macular degeneration, unspecified eye, advanced atrophic with subfoveal involvement
H35.32	Exudative age-related macular degeneration
H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.3290	Exudative age-related macular degeneration, unspecified eye, stage unspecified
H35.3291	Exudative age-related macular degeneration, unspecified eye, with active choroidal neovascularization
H35.3292	Exudative age-related macular degeneration, unspecified eye, with inactive choroidal neovascularization
H35.3293	Exudative age-related macular degeneration, unspecified eye, with inactive scar
H35.351	Cystoid macular degeneration, right eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 24 of 33

H35.352	Cystoid macular degeneration, left eye
H35.353	Cystoid macular degeneration, bilateral
H35.359	Cystoid macular degeneration, unspecified eye
H35.81	Retinal edema
H44.2A1	Degenerative myopia with choroidal neovascularization, right eye
H44.2A2	Degenerative myopia with choroidal neovascularization, left eye
H44.2A3	Degenerative myopia with choroidal neovascularization, bilateral eye
H44.2A9	Degenerative myopia with choroidal neovascularization, unspecified eye
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 25 of 33

E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 26 of 33

E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 27 of 33

E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 28 of 33

E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 29 of 33

E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye
E13.37X1	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye
E13.37X2	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye
E13.37X3	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral
E13.37X9	Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 30 of 33

VIII. REFERENCES:

1. EYLEA [package insert]. Tarrytown, NY: Regeneron. October 2024.
2. Age-related macular degeneration: Treatment and prevention https://www.uptodate.com/contents/age-related-macular-degeneration-treatment-and-prevention?search=age%20related%20macular%20degeneration&source=search_result&selectedTitle=1~65&usage_type=default&display_rank=1#H923348
3. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration <https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0161642012008652?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0161642012008652%3Fshowall%3Dtrue&referrer=https:%2F%2Fwww.ncbi.nlm.nih.gov%2F>
4. Retinal vein occlusion: Treatment https://www.uptodate.com/contents/retinal-vein-occlusion-treatment?search=macular%20edema%20following%20retinal%20vein%20occlusion&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
5. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema <https://www.nejm.org/doi/full/10.1056/NEJMoa1414264>
6. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA) <https://www.karger.com/Article/FullText/458539>
7. Diabetic Retinopathy Guidelines <https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2013-SCI-301-FINAL-DR-GUIDELINES-DEC-2012-updated-July-2013.pdf>
8. American Academy of Ophthalmology Retinal/Vitreous Panel. Age-related macular degeneration. Preferred Practice Pattern Guidelines. San Francisco, CA: AAO; 2019.
9. American Academy of Ophthalmology Retinal/Vitreous Panel. Diabetic retinopathy. Preferred Practice Pattern Guidelines. San Francisco, CA: AAO; 2019.
10. American Academy of Ophthalmology Retinal/Vitreous Panel. Retinal Vein Occlusions. Preferred Practice Pattern Guidelines. San Francisco, CA: AAO; 2019.
11. Astroz P, Balaratnasingam C, Yannuzzi LA. Cystoid macular edema and cystoid macular degeneration as a result of multiple pathogenic factors in the setting of central serous chorioretinopathy. Retin Cases Brief Rep. 2017;11 Suppl 1:S197-S201.
12. Bandello F, Berchicci L, La Spina C, et al. Evidence for anti-VEGF treatment of diabetic macular edema. Ophthalmic Res. 2012;48 Suppl 1:16-20.
13. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: Six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-1032.
14. Brue C, Pazzaglia A, Mariotti C, et al. Aflibercept as primary treatment for myopic choroidal neovascularisation: A retrospective study. Eye (Lond). 2016;30(1):139-145.
15. Cimerli (ranibizumab-eqrn) [package insert]. Redwood City, CA: Coherus BioSciences; May 2024.

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 31 of 33

16. Byooviz (ranibizumab-nuna) injection [package insert]. Cambridge, MA: Biogen; October 2023.
17. Susvimo (ranibizumab injection) [package insert]. South San Francisco, CA: Genentech; April 2022.
18. Vabysmo (faricimab-svoa) [package insert]. South San Francisco, CA: Genentech; July 2024.
19. Beovu (brolucizumab-dbll) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; July 2024.
20. Macugen [package insert]. Bridgewater, NJ; Valeant Pharmaceuticals North America LLC; July 2016.
21. Macugen. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: <http://www.micromedexsolutions.com>.
22. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology* 2005;112:1747-57.
23. Lucentis [package insert]. South San Francisco, CA; Genentech, Inc. February 2024.
24. Eylea HD [package insert]. Tarrytown, NY: Regeneron. October 2024.
25. Pavblu [package insert]. Thousand Oaks, CA: Amgen. August 2024.
26. Fierson WM. Screening Examination of Premature Infants for Retinopathy of Prematurity. *Pediatrics*. 2018;142(6):e20183061. doi:<https://doi.org/10.1542/peds.2018-3061>



Policy and Procedure

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 32 of 33

REVISION LOG:

REVISIONS	INITIAL	DATE
Creation date	SC	5/25/2023
Update	AKC	8/8/2023
Update	AKC	11/28/2023
Annual review	AKC	11/22/2024
Update	XZ	9/9/2025

Approved:

Date:

Suzana Patel

9/9/2025

**Suzana Patel, PharmD
Senior Director of Pharmacy**

Approved:

Date:

Sanjiv Shah

04.03.26

**Sanjiv Shah, MD
Chief Medical Officer**



Policy and Procedure

Title: UM-PT028 Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ocular Indications	Division: Medical Management Department: Pharmacy
Approval Date: 5/25/2023	LOB: Medicaid, HIV SNP, HARP, QHP, EP, Gold, GoldCare, CHP
Effective Date: 5/25/2023	Policy Number: UM-PT028
Review Date: 9/9/2025	Cross Reference Number:
Retired Date:	Page 33 of 33

Medical Guideline Disclaimer:

Property of MetroPlus HealthPlan. All rights reserved. The treating physician or primary care provider must submit MetroPlus Health Plan clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, Metroplus Health Plan will not be able to properly review the request for prior authorization. The clinical review criteria expressed in this policy reflects how MetroPlus Health Plan determines whether certain services or supplies are medically necessary. MetroPlus Health Plan established the clinical review criteria based upon a review of currently available clinical information(including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). MetroPlus Health Plan expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by MetroPlus Health Plan, as some programs exclude coverage for services or supplies that MetroPlus Health Plan considers medically necessary. If there is a discrepancy between this guidelines and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and website links are accurate at time of publication.

MetroPlus HealthPlan has adopted the herein policy in providing management, administrative and other services to our members, related to health benefit plans offered by our organization.